NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR)...
Cancer
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRPMELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc...
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel...
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment...
iPETcertum™ by Claritas, State-of-the-Art Software for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives Clearance from Brazilian Regulator ANVISA
NEW YORK and LONDON and SAO PAULO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed...
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2...
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational...
Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)
RGT-61159 is being evaluated in an ongoing multi-center, Phase 1a/b clinical trial in patients with advanced relapsed or refractory ACCWOBURN,...
Microbix Client Labquality Introduces Novel EQA Scheme at ESCV
Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck CancersMISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix...
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase...
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM,...
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers...
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab...
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company...
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4.Rapid,...
Deirdre Saulet, PhD, joins Jasper Health as Chief Strategy Officer
Brings Deep Expertise in Healthcare Strategy to Accelerate Jasper's Mission to Improve the Cancer Care Experience BOISE, Idaho, Sept. 16,...
Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
Children's Hospital of Philadelphia Researchers Find New Therapies Show Promise Against ALK-Driven Cancers PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Researchers...
DeepScribe Solidifies Ambient AI Leadership in Oncology with New Study and Accelerated Growth
Study links DeepScribe to improved diagnosis capture and clinician experience, underscoring impact of product innovations and rapid growth in oncology...